Abstract
Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PETs unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.
Keywords: Radiolabelled Tracers, Anticancer Drugs, Positron Emission Tomography pet, anti cancer therapy, anticancer angents, n dihmethylamino ethyl acridine carboxamide, temozolomide, f fdg, c thymidine, muti drug resistance mdr, hypoxia
Current Pharmaceutical Design
Title: Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET
Volume: 7 Issue: 18
Author(s): Frank Brady, Sajinder K. Luthra, Gavin D. Brown, Safiye Osman, Eric Aboagye, Azeem Saleem and Patricia M. Price
Affiliation:
Keywords: Radiolabelled Tracers, Anticancer Drugs, Positron Emission Tomography pet, anti cancer therapy, anticancer angents, n dihmethylamino ethyl acridine carboxamide, temozolomide, f fdg, c thymidine, muti drug resistance mdr, hypoxia
Abstract: Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PETs unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.
Export Options
About this article
Cite this article as:
Brady Frank, Luthra K. Sajinder, Brown D. Gavin, Osman Safiye, Aboagye Eric, Saleem Azeem and Price M. Patricia, Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET, Current Pharmaceutical Design 2001; 7 (18) . https://dx.doi.org/10.2174/1381612013396907
DOI https://dx.doi.org/10.2174/1381612013396907 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Head and Neck Cancer with Lung Metastases: Treatment Challenges
Clinical Cancer Drugs Translation of CYP2D6 Human Genetic Variation into Medical Practice: Lessons Learned and the Way Forward
Current Pharmacogenomics and Personalized Medicine Diphenylpentane Skeleton as a Multi-Template for Steroid Skeleton- Recognizing Receptors/Enzymes
Mini-Reviews in Medicinal Chemistry Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Synthesis and Preliminary Biological Evaluation of Estrone Dimers
Letters in Drug Design & Discovery Nitric Oxide Releasing Nanomaterials for Cancer Treatment: Current Status and Perspectives
Current Topics in Medicinal Chemistry METCAM/MUC18 Expression and Cancer Metastasis
Current Genomics A Review on the Development in the Field of NIDDM based Thiazolidinedione PPARγ Agonists
Mini-Reviews in Medicinal Chemistry Circulating Exosomes as Potential Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Exploring the Molecular Function of PIN1 by Nuclear Magnetic Resonance
Current Protein & Peptide Science Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Implication of Raft Microdomains in Drug Induced Apoptosis
Current Medicinal Chemistry - Anti-Cancer Agents Size-tuneable Nanometric MRI Contrast Agents for the Imaging of Molecular Weight Dependent Transport Processes
Pharmaceutical Nanotechnology Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Taking a Systems Approach to the Identification of Novel Therapeutic Targets and Biomarkers
Current Pharmaceutical Biotechnology Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Dendrimer-Curcumin Conjugate: A Water Soluble and Effective Cytotoxic Agent Against Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Rexinoids for Prevention and Treatment of Cancer: Opportunities and Challenges
Current Topics in Medicinal Chemistry The Bright Future of Radionuclides for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design